Sanofi

Sanofi ROE

The Return on Equity (ROE) of Sanofi (SAN.PA) as of Nov 4, 2026 is 10.95 %. In the previous year, Return on Equity (ROE) was 7.17 % — a change of 52.59% (higher).

ROE

10.95 %

YoY

52.59%

Last updated:

In 2025, Sanofi's return on equity (ROE) was 10.95 %, a 52.59% increase from the 7.17 % ROE in the previous year.

The Sanofi ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
7.31 EUR
Jan 1, 2019
4.67 EUR
Jan 1, 2020
19.51 EUR
Jan 1, 2021
9.06 EUR
Jan 1, 2022
11.44 EUR
Jan 1, 2023
7.29 EUR
Jan 1, 2024
7.17 EUR
Jan 1, 2025
10.95 EUR
The Sanofi ROE history
YEARROEYoY
10.95 %+52.59%
7.17 %-1.64%
7.29 %-36.27%
11.44 %+26.31%
9.06 %-53.57%
19.51 %+317.59%
4.67 %-36.11%
7.31 %-49.54%
14.49 %+77.13%
8.18 %+10.79%
7.39 %-5.59%
7.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sanofi Stock analysis

What does Sanofi do? Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide. Sanofi is one of the most popular companies on Eulerpool.

ROE Details

Decoding Sanofi's Return on Equity (ROE)

Sanofi's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Sanofi's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Sanofi's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Sanofi’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Sanofi stock

Return on Equity (ROE) of Sanofi is 10.95 % in 2025.

Return on Equity (ROE) of Sanofi changed from 7.17 % to 10.95 %, representing a 52.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Sanofi since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Sanofi with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Sanofi

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Sanofi